N

NovoCure Limited
D

NVCR

16.690
USD
-0.09
(-0.54%)
Market Closed
Volume
48,102
EPS
-2
Div Yield
-
P/E
-11
Market Cap
1,860,695,231
Related Instruments
BAX
BAX
0.200
(0.67%)
30.000 USD
C
CYH
0.01000
(0.30%)
3.31500 USD
E
EHC
-0.590
(-0.49%)
119.160 USD
HCA
HCA
0.40
(0.11%)
377.30 USD
H
HSTM
-0.820
(-2.99%)
26.600 USD
I
INGN
0.04000
(0.61%)
6.64000 USD
S
SEM
-0.095
(-0.64%)
14.845 USD
U
UHS
0.508
(0.30%)
171.718 USD
More
News

Title: NovoCure Limited

Sector: Healthcare
Industry: Medical Devices
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.